376 related articles for article (PubMed ID: 17637687)
21. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
[TBL] [Abstract][Full Text] [Related]
22. Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion.
Porter D; Levine JE
Semin Hematol; 2006 Jan; 43(1):53-61. PubMed ID: 16412789
[TBL] [Abstract][Full Text] [Related]
23. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
24. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation.
Lutz C; Massenkeil G; Nagy M; Neuburger S; Tamm I; Rosen O; Dörken B; Arnold R
Bone Marrow Transplant; 2008 May; 41(9):805-12. PubMed ID: 18195682
[TBL] [Abstract][Full Text] [Related]
25. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
26. Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation.
Rapanotti MC; Arcese W; Buffolino S; Iori AP; Mengarelli A; De Cuia MR; Cardillo A; Cimino G
Bone Marrow Transplant; 1997 Apr; 19(7):703-7. PubMed ID: 9156248
[TBL] [Abstract][Full Text] [Related]
27. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D
Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
Blair A; Goulden NJ; Libri NA; Oakhill A; Pamphilon DH
Blood Rev; 2005 Nov; 19(6):289-300. PubMed ID: 16275419
[TBL] [Abstract][Full Text] [Related]
29. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.
Raiola AM; Van Lint MT; Valbonesi M; Lamparelli T; Gualandi F; Occhini D; Bregante S; di Grazia C; Dominietto A; Soracco M; Romagnani C; Vassallo F; Casini M; Bruno B; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 2003 Apr; 31(8):687-93. PubMed ID: 12692609
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.
Schaap N; Schattenberg A; Mensink E; Preijers F; Hillegers M; Knops R; Pennings A; Boezeman J; Geurts van Kessel A; de Pauw B; de Witte T
Leukemia; 2002 Jan; 16(1):13-21. PubMed ID: 11840258
[TBL] [Abstract][Full Text] [Related]
31. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease.
Jiang YZ; Mavroudis DA; Dermime S; Molldrem J; Hensel NF; Barrett AJ
Bone Marrow Transplant; 1997 May; 19(9):899-903. PubMed ID: 9156263
[TBL] [Abstract][Full Text] [Related]
32. Donor leukocyte infusions in myeloid malignancies: new strategies.
Porter DL; Antin JH
Best Pract Res Clin Haematol; 2006; 19(4):737-55. PubMed ID: 16997180
[TBL] [Abstract][Full Text] [Related]
33. Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions.
Cwynarski K; Goulding R; Pocock C; Dazzi F; Craddock C; Kaeda J; Olavarria E; Kanfer E; Apperley J; Lawler M; Goldman JM
Bone Marrow Transplant; 2001 Sep; 28(6):581-6. PubMed ID: 11607771
[TBL] [Abstract][Full Text] [Related]
34. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse.
Carlens S; Remberger M; Aschan J; Ringdén O
Biol Blood Marrow Transplant; 2001; 7(1):31-8. PubMed ID: 11215696
[TBL] [Abstract][Full Text] [Related]
35. Mixed chimerism is frequent after allogeneic peripheral blood stem cell transplantation with positive CD34 selection, and is not reverted by low doses of donor T-cells add-back.
Rodríguez-Luaces M; Ferrá C; Martín-Henao G; Berlanga JJ; Grañena A; Gallardo D
Eur J Haematol; 2004 Sep; 73(3):162-8. PubMed ID: 15287912
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.
Or R; Hadar E; Bitan M; Resnick IB; Aker M; Ackerstein A; Samuel S; Tsirigotis P; Gesundheit B; Slavin S; Shapira MY
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1295-301. PubMed ID: 17162211
[TBL] [Abstract][Full Text] [Related]
37. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
[TBL] [Abstract][Full Text] [Related]
38. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions.
Datta AR; Barrett AJ; Jiang YZ; Guimarães A; Mavroudis DA; van Rhee F; Gordon AA; Madrigal A
Bone Marrow Transplant; 1994 Oct; 14(4):517-24. PubMed ID: 7858526
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
[TBL] [Abstract][Full Text] [Related]
40. Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity.
Durakovic N; Radojcic V; Powell J; Luznik L
Transplantation; 2007 Mar; 83(5):631-40. PubMed ID: 17353785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
